DBV Technologies Releases FY 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Source: seekingalpha
- Financial Performance: DBV Technologies reported a GAAP EPS of -$1.05 for FY 2025, indicating ongoing challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, DBV held $194.2 million in cash and cash equivalents, a significant increase from $32.5 million in 2024, reflecting improved cash management practices.
- Operating Cash Usage: The net cash used for operating activities was $121.2 million in 2025 compared to $104.5 million in 2024, highlighting that despite increased cash reserves, high operational expenditures remain a significant financial pressure for the company.
- Industry Engagement: DBV Technologies is set to present at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting, indicating active participation in the industry that may pave the way for future collaborations and funding opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DBVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DBVT
Wall Street analysts forecast DBVT stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.350
Low
40.00
Averages
46.40
High
51.00
Current: 17.350
Low
40.00
Averages
46.40
High
51.00
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DBV Technologies Half-Year Report on Liquidity Contract with ODDO BHF
- Liquidity Contract Overview: Since the implementation of the liquidity contract with ODDO BHF on July 1, 2018, DBV Technologies has seen its liquidity account assets increase from 41,159 shares to 146,321 shares, indicating a significant enhancement in stock liquidity and boosting market confidence.
- Trading Activity Analysis: In the first half of 2026, DBV executed 1,989 buy transactions and 2,012 sell transactions, with trading volumes of 2,707,915 shares and 2,636,174 shares respectively, reflecting high market activity that could improve the company's stock performance.
- Financial Condition Changes: As of June 30, 2026, the liquidity account held a cash balance of €396,088.22, down from €527,891.63 on December 31, 2025, highlighting the impact of market fluctuations on the company's liquidity management.
- Strategic Positioning: DBV Technologies is focused on developing treatment options for food allergies using its proprietary VIASKIN® technology in clinical trials, aiming to meet the urgent market demand for safe and effective therapies, thereby solidifying its leadership in the biopharmaceutical sector.
See More
DBV Technologies Updates BLA Submission for VIASKIN® Peanut Patch
- FDA Collaboration Progress: DBV Technologies has engaged in extensive discussions with the FDA to ensure an efficient and timely review of the Biologics License Application (BLA) for the VIASKIN® Peanut Patch in children aged 4 to 7, demonstrating the company's proactive approach to regulatory compliance.
- Submission Timeline Expectation: DBV anticipates filing the BLA in the third quarter of 2026, and while additional time is needed to incorporate FDA feedback, the absence of requests for further data indicates a strong preparation and completeness of the application materials.
- Product Innovation Context: The VIASKIN® Peanut Patch represents a novel and complex product aimed at treating food allergies through epicutaneous immunotherapy (EPIT), with DBV committed to addressing this significant unmet medical need, particularly within the pediatric population.
- Investor Communication Arrangement: DBV will host an investor conference call on June 29, 2026, at 5:00 PM ET to discuss the latest developments regarding the BLA submission, enhancing transparency and trust with investors.
See More
DBV Technologies Included in Euronext Tech Leaders Index
- Inclusion in Tech Leaders Index: DBV Technologies was officially included in the Euronext Tech Leaders index on June 22, 2026, which is expected to enhance the company's visibility in the European market and attract more institutional investors to its innovative capabilities and growth potential.
- Innovative Treatment Options: The company focuses on developing the VIASKIN® Peanut Patch, aimed at providing a potential new treatment option for children with peanut allergies, which, if approved, could significantly improve the quality of life for millions of families.
- Market Positioning: The Euronext Tech Leaders index unites over 100 high-growth European companies, and DBV's inclusion not only highlights its innovative standing in the biopharmaceutical sector but may also strengthen its strategic advantage in a competitive market.
- Future Outlook: DBV Technologies CEO Daniel Tassé stated that this recognition reflects the strength of the company's science and progress, and they will continue to focus on improving care for food allergy patients through EPIT technology, driving long-term growth for the company.
See More
DBV Technologies Presents Positive VITESSE Study Data at EAACI Congress 2026
- VITESSE Study Results: The Phase 3 VITESSE study demonstrated that the VIASKIN® Peanut Patch showed significant efficacy in children aged 4 to 7 with peanut allergies, with a response rate of 46.6% at 12 months compared to 14.9% in the placebo group among 654 participants, indicating potential clinical value in treating children with concomitant atopic conditions like asthma.
- Clinical Trial Design: DBV Technologies will present the design of its newly initiated THRIVE Phase 2 study at the EAACI Congress, which aims to assess the safety and efficacy of the VIASKIN® Peanut Patch in infants aged 6 to 12 months, enrolling approximately 250 participants, with results expected to inform future immunotherapy protocols.
- Comorbidity Prevalence: The VITESSE study revealed that 35.8% of participants had asthma, 56.6% had additional food allergies, and 61.8% had atopic dermatitis, highlighting the high prevalence of multiple allergic comorbidities in children with peanut allergies and the need for targeted treatment options.
- Potential for Early Intervention: DBV's Chief Medical Officer emphasized that the successful application of the VIASKIN® Peanut Patch could provide new treatment options for early intervention, helping to shape long-term allergy management strategies and further enhancing the company's market position in the food allergy sector.
See More
DBV Technologies to Participate in Goldman Sachs Global Healthcare Conference
- Goldman Sachs Conference: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, showcasing the company's advancements in food allergy treatments, which is expected to attract investor interest.
- Technological Innovation: The company focuses on developing its proprietary VIASKIN® patch technology, designed to introduce microgram amounts of biologically active compounds through the skin, aiming to non-invasively re-educate the immune system to alleviate food allergy symptoms, presenting significant market potential.
- Clinical Trial Progress: DBV is currently conducting clinical trials of the VIASKIN Peanut patch for peanut-allergic toddlers and children aged 1 to 7, and successful outcomes could significantly improve the quality of life for millions of children, enhancing the company's leadership position in the biopharmaceutical sector.
- Market Positioning: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its global market strategy and investment appeal.
See More
DBV Technologies Holds 2026 General Meeting with All Resolutions Approved
- General Meeting Outcome: DBV Technologies held its General Meeting on June 3, 2026, in Châtillon, France, where shareholders approved all proposed resolutions, reflecting investor confidence in the company's future direction.
- Technological Innovation: The company focuses on developing its proprietary VIASKIN® patch technology aimed at treating food allergies through epicutaneous immunotherapy, addressing significant unmet medical needs for millions of patients, which presents substantial market potential.
- Clinical Trial Progress: DBV is currently conducting clinical trials for the VIASKIN Peanut Patch targeting food-allergic children aged 1 to 7 years, aiming to enhance patient quality of life through a non-invasive treatment approach.
- Market Positioning: DBV Technologies' ordinary shares are traded on Euronext Paris, while its ADSs are listed on Nasdaq, showcasing its strategic positioning in the global market and attractiveness to investors.
See More
DBV Technologies Half-Year Report on Liquidity Contract with ODDO BHF
- Liquidity Contract Overview: Since the implementation of the liquidity contract with ODDO BHF on July 1, 2018, DBV Technologies has seen its liquidity account assets increase from 41,159 shares to 146,321 shares, indicating a significant enhancement in stock liquidity and boosting market confidence.
- Trading Activity Analysis: In the first half of 2026, DBV executed 1,989 buy transactions and 2,012 sell transactions, with trading volumes of 2,707,915 shares and 2,636,174 shares respectively, reflecting high market activity that could improve the company's stock performance.
- Financial Condition Changes: As of June 30, 2026, the liquidity account held a cash balance of €396,088.22, down from €527,891.63 on December 31, 2025, highlighting the impact of market fluctuations on the company's liquidity management.
- Strategic Positioning: DBV Technologies is focused on developing treatment options for food allergies using its proprietary VIASKIN® technology in clinical trials, aiming to meet the urgent market demand for safe and effective therapies, thereby solidifying its leadership in the biopharmaceutical sector.
See More
DBV Technologies Updates BLA Submission for VIASKIN® Peanut Patch
- FDA Collaboration Progress: DBV Technologies has engaged in extensive discussions with the FDA to ensure an efficient and timely review of the Biologics License Application (BLA) for the VIASKIN® Peanut Patch in children aged 4 to 7, demonstrating the company's proactive approach to regulatory compliance.
- Submission Timeline Expectation: DBV anticipates filing the BLA in the third quarter of 2026, and while additional time is needed to incorporate FDA feedback, the absence of requests for further data indicates a strong preparation and completeness of the application materials.
- Product Innovation Context: The VIASKIN® Peanut Patch represents a novel and complex product aimed at treating food allergies through epicutaneous immunotherapy (EPIT), with DBV committed to addressing this significant unmet medical need, particularly within the pediatric population.
- Investor Communication Arrangement: DBV will host an investor conference call on June 29, 2026, at 5:00 PM ET to discuss the latest developments regarding the BLA submission, enhancing transparency and trust with investors.
See More
DBV Technologies Included in Euronext Tech Leaders Index
- Inclusion in Tech Leaders Index: DBV Technologies was officially included in the Euronext Tech Leaders index on June 22, 2026, which is expected to enhance the company's visibility in the European market and attract more institutional investors to its innovative capabilities and growth potential.
- Innovative Treatment Options: The company focuses on developing the VIASKIN® Peanut Patch, aimed at providing a potential new treatment option for children with peanut allergies, which, if approved, could significantly improve the quality of life for millions of families.
- Market Positioning: The Euronext Tech Leaders index unites over 100 high-growth European companies, and DBV's inclusion not only highlights its innovative standing in the biopharmaceutical sector but may also strengthen its strategic advantage in a competitive market.
- Future Outlook: DBV Technologies CEO Daniel Tassé stated that this recognition reflects the strength of the company's science and progress, and they will continue to focus on improving care for food allergy patients through EPIT technology, driving long-term growth for the company.
See More
DBV Technologies Presents Positive VITESSE Study Data at EAACI Congress 2026
- VITESSE Study Results: The Phase 3 VITESSE study demonstrated that the VIASKIN® Peanut Patch showed significant efficacy in children aged 4 to 7 with peanut allergies, with a response rate of 46.6% at 12 months compared to 14.9% in the placebo group among 654 participants, indicating potential clinical value in treating children with concomitant atopic conditions like asthma.
- Clinical Trial Design: DBV Technologies will present the design of its newly initiated THRIVE Phase 2 study at the EAACI Congress, which aims to assess the safety and efficacy of the VIASKIN® Peanut Patch in infants aged 6 to 12 months, enrolling approximately 250 participants, with results expected to inform future immunotherapy protocols.
- Comorbidity Prevalence: The VITESSE study revealed that 35.8% of participants had asthma, 56.6% had additional food allergies, and 61.8% had atopic dermatitis, highlighting the high prevalence of multiple allergic comorbidities in children with peanut allergies and the need for targeted treatment options.
- Potential for Early Intervention: DBV's Chief Medical Officer emphasized that the successful application of the VIASKIN® Peanut Patch could provide new treatment options for early intervention, helping to shape long-term allergy management strategies and further enhancing the company's market position in the food allergy sector.
See More
DBV Technologies to Participate in Goldman Sachs Global Healthcare Conference
- Goldman Sachs Conference: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, showcasing the company's advancements in food allergy treatments, which is expected to attract investor interest.
- Technological Innovation: The company focuses on developing its proprietary VIASKIN® patch technology, designed to introduce microgram amounts of biologically active compounds through the skin, aiming to non-invasively re-educate the immune system to alleviate food allergy symptoms, presenting significant market potential.
- Clinical Trial Progress: DBV is currently conducting clinical trials of the VIASKIN Peanut patch for peanut-allergic toddlers and children aged 1 to 7, and successful outcomes could significantly improve the quality of life for millions of children, enhancing the company's leadership position in the biopharmaceutical sector.
- Market Positioning: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its global market strategy and investment appeal.
See More
DBV Technologies Holds 2026 General Meeting with All Resolutions Approved
- General Meeting Outcome: DBV Technologies held its General Meeting on June 3, 2026, in Châtillon, France, where shareholders approved all proposed resolutions, reflecting investor confidence in the company's future direction.
- Technological Innovation: The company focuses on developing its proprietary VIASKIN® patch technology aimed at treating food allergies through epicutaneous immunotherapy, addressing significant unmet medical needs for millions of patients, which presents substantial market potential.
- Clinical Trial Progress: DBV is currently conducting clinical trials for the VIASKIN Peanut Patch targeting food-allergic children aged 1 to 7 years, aiming to enhance patient quality of life through a non-invasive treatment approach.
- Market Positioning: DBV Technologies' ordinary shares are traded on Euronext Paris, while its ADSs are listed on Nasdaq, showcasing its strategic positioning in the global market and attractiveness to investors.
See More
